Bioxytran Inc.

BIXT on OTCQBToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.44US -0.06/-12.20%18,5130.14 / 1.9637.96 M

Contact Information

Bioxytran Inc.

Headquarters:
233 Needham St. , Suite 300
Boston, Massachusetts
USA, 02464
Tel: 617-454-1199
Email: Send a message
Website: Visit website
For more information...
Lead: Steve Hosein

Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on anew molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics are d blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. 

David Platt PhD - CEO & Chairman

Ola Soderquist CPA, CMA, CM&AA - CFO

Elena Chekhova PhD - Chief Scientist

David Platt - CEO & Chairman

Anders N. Utter - Director

Alan M. Hoberman - Director

Henry J. Esber - Director

Dale H. Conaway - Director

Stock Information

Company Overview

Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on anew molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics are d blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. 

Management

David Platt PhD - CEO & Chairman

Ola Soderquist CPA, CMA, CM&AA - CFO

Elena Chekhova PhD - Chief Scientist

Board of Directors

David Platt - CEO & Chairman

Anders N. Utter - Director

Alan M. Hoberman - Director

Henry J. Esber - Director

Dale H. Conaway - Director

Contact Information

Headquarters:
233 Needham St. , Suite 300
Boston, Massachusetts
02464, USA
Telephone: 617-454-1199
Email: Send a message
Website: Visit website